Key result
Peptides I and II encapsulated in liposomes protected 60% and 80% of guinea pigs, respectively, from FMDV challenge compared to 0% protection in control groups.
Peptides I and II from FMDV VP1 encapsulated in liposomes act as CTL epitopes and provide partial protection against FMDV challenge in a guinea pig model.
Answers are grounded in this paper and cite their sources.
Partial protection in guinea pigs supports further testing; leaves open translation to livestock or field use.
It has been predicted that nonameric peptides I (VP1(26-34), RRQHTDVSF), II (VP1(157-165), RTLPTSFNY) and III (VP1(45-53), KEQVNVLDL) from the VP1 capsid protein of the foot-and-mouth disease virus (FMDV) are T cell epitopes. To investigate whether these peptides have immunological activity, BALB/c mice were immunized with peptide I, II or III conjugated with immunostimulating complexes (ISCOMs). A cytotoxic T lymphocyte assay was used to evaluate the cytotoxic activity induced by peptides along with by measuring peptide-specific T-cell proliferation and CD8(+) T lymphocyte numbers in whole blood and interferon (IFN)-γ production in peripheral blood mononuclear cells induced by peptides. To further identify the protective efficacy of peptides, an FMDV challenge assay was done in guinea pigs. Peptides I and II stimulated significant increases in T-cell proliferation, CD8(+) T lymphocytes, and IFN-γ secretion and cytotoxic activity compared to controls. The FMDV challenge assay indicated peptides I and II can protect over 60% of animals from virus attack. The results demonstrate that peptides I and II encapsulated in liposomes should be CTL epitopes of FMDV and can protect animals from virus attack to some extent.
No takes yet. Share an insight, caveat, or question.
Feng-shan et al. (2013) studied Foot-and-mouth disease virus (FMDV) infection (n=165). FMDV nonameric peptides I and II encapsulated in liposomes vs. PBS, liposomes alone, or unrelated peptides was evaluated on Protection against FMDV challenge in guinea pigs. Peptides I and II encapsulated in liposomes protected 60% and 80% of guinea pigs, respectively, from FMDV challenge compared to 0% protection in control groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: